| Code | CSB-YP013227HU1 |
| Abbreviation | Recombinant Human LTBR protein, partial (Active) |
| MSDS | |
| Size | $250 |
| Order now | |
| Image |
|
| Have Questions? | Leave a Message or Start an on-line Chat |
Lymphotoxin-beta receptor plays a central role in lymphoid organogenesis and immune homeostasis, making its extracellular domain (aa 31–227) a critical tool for dissecting TNF superfamily signaling networks. This yeast-expressed construct demonstrates robust binding to both a recombinant anti-LTBR antibody (EC50 0.53–0.61 ng/mL) and its natural ligand TNFSF14/LIGHT (EC50 7.3–8.9 ng/mL) in functional ELISA, providing quantitative evidence of preserved conformational epitopes suitable for competitive inhibition assays and therapeutic antibody epitope mapping. The low endotoxin level (<1.0 EU/μg) combined with >95% purity supports use in ligand-binding screens where inflammatory background must be minimized, including SPR-based affinity characterization and blocking antibody validation campaigns. Researchers investigating TNF receptor superfamily crosstalk or developing biologics targeting LTBR-mediated pathways will find the dual-validated binding activity particularly valuable for establishing dose-response curves in drug discovery workflows.
There are currently no reviews for this product.